Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MRD-positive”

95 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 95 results

Not applicableLooking for participantsNCT07214532
What this trial is testing

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Who this might be right for
Breast NeoplasmsCarcinoma, Ductal, BreastReceptors, Estrogen (for ER-positive Requirement)
Natera, Inc. 725
Not applicableUnknownNCT05603156
What this trial is testing

Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive

Who this might be right for
Ph+ ALLBone Marrow TransplantMinimal Residual Disease
Institute of Hematology & Blood Diseases Hospital, China 46
Not applicableLooking for participantsNCT05433753
What this trial is testing

Asian Multicenter Prospective Study in HER2 Positive Early Breast Cancer for Detecting MRD by ctDNA;HARMONY Study

Who this might be right for
HER2-positive Breast Cancer
National Cancer Center, Japan 60
Testing effectiveness (Phase 2)Looking for participantsNCT05940961
What this trial is testing

Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL

Who this might be right for
ALLMRD-positiveHematopoietic Stem Cell Transplantation
Sheng-Li Xue, MD 42
Not applicableUnknownNCT05795010
What this trial is testing

MRD Test in Common Risk Stage II Colorectal Cancer

Who this might be right for
Stage II Colorectal Cancer
First Affiliated Hospital Xi'an Jiaotong University 60
Early research (Phase 1)Ended earlyNCT05001451
What this trial is testing

Study of GDX012 in Patients With MRD Positive AML

Who this might be right for
Acute Myeloid Leukemia
GammaDelta Therapeutics Limited 3
Testing effectiveness (Phase 2)WithdrawnNCT05604755
What this trial is testing

Prophylactic HQP1351 Therapy Post-transplants on Leukemia After Allo-HSCT

Who this might be right for
Prophylactic HQP1351 TherapyThird Generation TKI
xuna
Testing effectiveness (Phase 2)UnknownNCT05821738
What this trial is testing

Avapritinib in CBF-AML With KIT Mutations

Who this might be right for
Core Binding Factor Acute Myeloid LeukemiaKIT Mutation-Related Tumors
The First Affiliated Hospital of Soochow University 50
Testing effectiveness (Phase 2)UnknownNCT03992170
What this trial is testing

Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive

Who this might be right for
Myeloma Multiple
Azienda Ospedaliera Universitaria Senese 50
Not applicableStudy completedNCT02010931
What this trial is testing

Retrospective Analysis of Survival in Adult MRD Positive Acute Lymphoblastic Leukemia Patients

Who this might be right for
Acute Lymphoblastic Leukemia
Amgen 310
Testing effectiveness (Phase 2)Ended earlyNCT03523429
What this trial is testing

PETHEMA-BLIN-01/PET069014 (BLIN-01)

Who this might be right for
Philadelphia Chromosome-negative or BCR-ABL-negative, CD19-positive ALL
PETHEMA Foundation 11
Testing effectiveness (Phase 2)Looking for participantsNCT06517212
What this trial is testing

Tirzepatide Weight Loss for MRD+ Early Breast Cancer

Who this might be right for
Breast CancerBreast NeoplasmsBreast Cancers
Baylor Research Institute 48
Testing effectiveness (Phase 2)Looking for participantsNCT07507318
What this trial is testing

Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission

Who this might be right for
Diffuse Large B-Cell Lymphoma
Rong Tao 69
Not applicableNot Yet RecruitingNCT07132502
What this trial is testing

Treatment Intermittent Periods Based on ctDNA-MRD（Circulating Tumor DNA-minimal Residual Disease） Status in Advanced HER2-Positive Breast Cancer

Who this might be right for
Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 24
Not applicableLooking for participantsNCT07131059
What this trial is testing

MRD-positive AML Clinical Study

Who this might be right for
AML, Adult
Institute of Hematology & Blood Diseases Hospital, China 537
Testing effectiveness (Phase 2)Ended earlyNCT04216563
What this trial is testing

ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor

Who this might be right for
Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center 7
Not applicableStudy completedNCT03751072
What this trial is testing

Efficacy and Toxicity of Blinatumomab in the French ATU for Adult BCP-ALL R/R, or With MRD+ (FRENCH-CYTO)

Who this might be right for
Acute Lymphoblastic Leukemia, in RelapseAcute Lymphoblastic Leukemia With Failed Remission
Group for Research in Adult Acute Lymphoblastic Leukemia 92
Not applicableLooking for participantsNCT07211178
What this trial is testing

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

Who this might be right for
Breast CancerTNBC - Triple-Negative Breast CancerHR Positive/HER-2 Negative Breast Cancer+2 more
Tempus AI 900
Large-scale testing (Phase 3)Looking for participantsNCT07441291
What this trial is testing

CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT

Who this might be right for
B ALLAllogenetic Hematopoietic Stem Cell TransplantationMRD-positive
Peking University People's Hospital 70
Testing effectiveness (Phase 2)Active Not RecruitingNCT07134088
What this trial is testing

Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

Who this might be right for
Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic LeukemiaMinimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia
Amgen 104
Next Page